Choanal atresia is a rare complication of radiation for nasopharyngeal carcinoma, which has to be early detected. Its treatment is based on endoscopic endonasale surgery. We report a rare case of choanal stenosis observed in a 54-year-old patient, Ho presented 4 years after the end of radiotherapy for nasopharyngeal carcinoma, a progressive bilateral nasal obstruction, anosmia, and rhinorrhea without bleeding. The diagnostic of fibrous stenosis was confirmed by endonasal endoscopic examination coupled to CT scan of nasopharynx. The recanalization via endoscopic endonasal surgery with tube calibration gave a great functional result with the improvement of nasal symptoms. Even after 6 months of follow-up, there were no signs of restenosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945375 | PMC |
| http://dx.doi.org/10.11604/pamj.2019.34.111.18968 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.
BMC Med
March 2025
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Background: We aimed to evaluate the efficacy and safety of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin, and capecitabine) in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who failed to PD-1 inhibitor-containing regimens.
Methods: In this single-arm, open-label, phase 2 study, RM-NPC patients who failed to at least one line of systemic chemotherapy and anti-PD-1 immunotherapy were enrolled and received cadonilimab plus TPC chemotherapy every 3 weeks for up to 6 cycles, followed by cadonilimab plus capecitabine every 3 weeks for a maximum of 2 years. The primary endpoint was the objective response rate (ORR).
Schisandrin B targets CDK4/6 to suppress proliferation and enhance radiosensitivity in nasopharyngeal carcinoma by inducing cell cycle arrest.
Sci Rep
March 2025
The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Affiliated Zhongshan Hospital of Dalian University, No.6 Jiefang Street, Zhongshan District, Dalian, 116001, Liaoning, China.
Nasopharyngeal carcinoma (NPC) is notably prevalent in East and Southeast Asia, where despite advancements in radiotherapy leading to high control rates, challenges like radioresistance and collateral tissue damage remain significant. While Schisandrin B (SchB) has been demonstrated antitumor effects in various tumors, its efficacy in NPC remains unexplored. In this study, we explored the antitumor potential of Sch B on NPC, particularly its effects on cell proliferation and radiosensitivity.
View Article and Find Full Text PDFThyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study.
Oral Oncol
March 2025
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China. Electronic address:
Purpose: This study aimed to investigate the ability of thyroid volumes after intensity-modulated radiotherapy (IMRT) to predict the incidence of radiation-induced hypothyroidism/primary hypothyroidism (HT)/(PHT) in nasopharyngeal carcinoma (NPC) patients.
Methods And Materials: 404 NPC patients were retrospectively enrolled from January 2015 to January 2019. Thyroid volumes were calculated based on magnetic resonance imaging.
Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review.
Naunyn Schmiedebergs Arch Pharmacol
March 2025
Department of Pharmacy, Panipat Institute of Engineering and Technology (PIET), Samalkha, Panipat, 132102, Haryana, India.
This manuscript is aimed at preparing a scientific report on anticancer drugs, covering pharmacological aspects, approved by the FDA in the year 2023. This article is anticipated to serve as a handy document of interest for oncologists, patients as well as academicians. The manuscript was prepared by studying the pre-clinical and clinical data available in the public domain specifically on the website of the USFDA, Clinical Trials, National Library of Medicine, and other sources.
View Article and Find Full Text PDFA Rare Case of Nasopharyngeal Adenocarcinoma Presenting with Vernet's Syndrome.
Indian J Otolaryngol Head Neck Surg
January 2025
Department of Oto Rhino Laryngology, Faculty of Medicine-Sri Lalithambigai Medical College and Hospital, Dr. M.G.R. Educational and Research Institute, Chennai, 600095 Tamil Nadu India.
A rare case of Nasopharyngeal Adeno Carcinoma [NAC] causing Vernet's Syndrome in a 59 years old male is reported. Brief recap of NAC pathology, classification, literature review, the clinical history, misleading signs, missed diagnosis and the value of careful history taking and detailed examination are presented.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!